Xcenda’s Tasmina Hydery and Anne Loos shared their thoughts on the methodologies used by the Institute for Clinical and Economic Review (ICER) in its Unsupported Price Increase (UPI) assessments. Payers are increasingly incorporating these ICER reviews in their coverage decision-making processes.
“Manufacturers whose products are selected for review should be prepared to justify their cost and value with data-supported input, including, for example, real-world evidence, meta-analyses, and/or economic models, where appropriate. ICER is consistently evolving its approach to UPI assessments; so, it is important to stay informed of any changes to the methodology, timelines for providing feedback, and findings that might impact discussions with payers.” Read more here.
(Source: Tasmina Hydery & Anne Loos, Xcenda – AmerisourceBergen, 7/1/21)